Protalix BioTherapeutics

Historical price data

Protalix BioTherapeutics is a mission-driven company focused on transforming the treatment of rare diseases through its innovative plant cell-based protein expression platform, ProCellEx®. Its achievements include the successful FDA approval and commercialization of Elelyso® for Gaucher disease and a second approved product, establishing it as a leader in novel biologics manufacturing. The company's strategy centers on advancing its internal pipeline in lysosomal storage disorders while actively seeking strategic collaborations to expand the reach of its validated technology platform.

ProCellEx® is a proprietary plant cell-based protein expression system using genetically engineered carrot or tobacco cells to produce recombinant therapeutic proteins with targeted glycosylation and enhanced safety profiles.

Protalix faces product competition from established enzyme replacement therapies for Gaucher and Fabry disease. Its technological edge lies in its proven plant-based ProCellEx® platform, which differentiates on safety, cost, and the ability to produce proteins with optimized glycosylation for enhanced targeting.